Aprocitentan

(Tryvio®)

Tryvio®

Drug updated on 12/11/2024

Dosage FormTablet (oral; 12.5 mg)
Drug ClassEndothelin receptor antagonists
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs
  • Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of one systematic review/meta-analysis. [1]
  • Aprocitentan (Tryvio) and other novel drugs, including non-steroid mineralocorticoid receptor antagonists and selective aldosterone synthase inhibitors, have shown effectiveness in lowering seated office and 24-hour ambulatory systolic/diastolic blood pressure in patients with resistant hypertension (RHT) when added to a regimen of 2-3 antihypertensive drugs.
  • The effectiveness of these drugs, including aprocitentan as a dual endothelin receptor antagonist, has been demonstrated in phase 2 randomized controlled trials (RCTs) for RHT patients, but the review does not specify comparative effectiveness between aprocitentan and other novel drug classes.
  • No differences in effectiveness across population subgroups or types were detailed in the review for the RHT patient population.
  • There is no safety information available in the reviewed studies.

Product Monograph / Prescribing Information

Document TitleYearSource
Tryvio (aprocitentan) Prescribing Information.2024Idorsia Pharmaceuticals US Inc., Radnor, PA

Systematic Reviews / Meta-Analyses